Lab Reagents and Resources

Prediman Krishan Shah, MD, and Behrooz Sharifi, PhD, resources for current animal models developed for atherosclerosis research:

• Mouse Model for Myocardial Infarction
• Aortic Construction: A Technique to Produce Left Ventricular Hypertrophy in Mice
• Mouse Cervical Cardiac Transplantation
• Artery Injury Model for Atherosclerosis
• Directed Vascular Graft Regeneration in Mice Peritoneal Cavity
• Peritoneal Cavity Bone Marrow Transplantation for Gene Therapy and Atherosclerosis

Shah and Sharifi resources for knock-out mouse models:

• Tenascin-C (TNC) KO
• Pleiotrophin (PTN) KO
• GATA3 Gene Conditional (GATA3) KO
• Krüppel-like Factor 14 (KLF14) KO
• Apolipoprotein E / Apolipoprotein A1 (ApoE/ApoA1) KO
• Delta DBL GATA KO (Eosinophils KO)
• Eotaxin 1,2 KO
• C57 BL6-Tg (Marfia)

Shah clinical protocols:

• A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects with Severe Familial Hypercholesterolemia (TAUSSIG: Trial Assessing long-term USe of PCSK9 Inhibition in Subject with Genetic LDL Disorders; Protocol 20110271)
• A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects (Protocol 20120332;GAUSS-3)
• Open-Label Extension Study of EFC12492, R727-CL1112, EFC12732 & LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
• LOWER: Lomitapide Observational Worldwide Evaluation Registry
• A Multicenter, Controlled, Open-Label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Protocol 20120138; OSLER-2 Open Label Study of Long-Term Evaluation Against LDL-C Trial)

Kuang-Yuh Chyu, MD, PhD, and Paul Dimayuga, PhD, resources for current animal studies developed for atherosclerosis research:

• Role of Cathelin-Related Anti-Microbial Peptide (CRAMP)-specific CD8+ T cells in atherosclerosis
• Role of CD8+ regulatory T cells in atherosclerosis
• Comparison of 15 ApoB-100 peptide based vaccines
• Role of DC in ApoB-100 peptide vaccine
• Effect of p210 based immunization on AAA and hypertension 
• Effect of lipid lowering on immune function in ApoE (-/-) mice
• Screening for efficacy of different formulations of p210 vaccine
• Role of CD8+ T regulatory cells in the protective effect of a peptide vaccine against atherosclerosis
• Effect of immunization with an ApoB-100 peptide, p210, on Kawasaki disease (KD) vasculitis
• Efficacy of immunization with p210-based vaccines in modulating transplant vasculopathy
• Characterization of p210 specific CD8+ T cells in murine and human atherosclerosis
• Development of accelerated atherosclerosis in an SLE model in ApoE (-/-) mice
• Characterization of immune responses to p210 vaccines in murine model of atherosclerosis 
• Atherosclerotic mouse model transgenic for Class-I HLA0201
• Discovery and screening of peptide self-antigens in coronary artery disease